Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Mautino
Giséle Mautino, Chenneviere Sur Marne FR
| Patent application number | Description | Published |
|---|---|---|
| 20110105475 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS - The present invention relates to compounds of formula (I) wherein the substituents are as defined in the claims, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention and/or amelioration of one or more symptoms of disease or disorders related to the activity of FXR. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I). | 05-05-2011 |
Giséle Mautino, Chenneviere Sur Marne FR
| Patent application number | Description | Published |
|---|---|---|
| 20110105475 | BENZOFURANE, BENZOTHIOPHENE, BENZOTHIAZOL DERIVATIVES AS FXR MODULATORS - The present invention relates to compounds of formula (I) wherein the substituents are as defined in the claims, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention and/or amelioration of one or more symptoms of disease or disorders related to the activity of FXR. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I). | 05-05-2011 |
Mario Mautino, Ames, IA US
| Patent application number | Description | Published |
|---|---|---|
| 20110053941 | IDO Inhibitors - Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein. | 03-03-2011 |
Mario R. Mautino, Ankeny, IA US
| Patent application number | Description | Published |
|---|---|---|
| 20090060930 | Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes - The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal. | 03-05-2009 |
| 20110136796 | IDO Inhibitors - Presently provided are compounds according to the formula (I) or (II), and pharmaceutical compositions comprising the compounds, wherein R | 06-09-2011 |
| 20120003251 | ENHANCED IMMUNOGENICITY OF TUMOR ASSOCIATED ANTIGENS BY ADDITION OF ALPHAGAL EPITOPES - The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epi topes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal. | 01-05-2012 |
Peter S. Mautino, Pittsburgh, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20120175905 | Method and System for Manufacturing a Wheel - A system for manufacturing a wheel includes a cope mold portion comprising internal cope mold walls and a drag mold portion comprising internal drag mold walls. The internal walls define at least in part perimeter boundaries of a wheel cavity. The wheel cavity comprises a cavity center portion configured to form a wheel center portion of a wheel after solidification of a molten alloy in the cavity center portion, a cavity plate portion configured to form a wheel plate portion of the wheel after solidification of a molten alloy in the cavity plate portion, and a cavity flange portion configured to form a wheel flange portion of the wheel after solidification of a molten alloy in the cavity flange portion. The system includes a chill component configured to provide directional solidification from the cavity flange portion toward the cavity plate portion of molten alloy in the wheel cavity. | 07-12-2012 |
P. Scott Mautino, Pittsburgh, PA US
| Patent application number | Description | Published |
|---|---|---|
| 20100326943 | Railcar Coupler System and Method - A railcar coupler includes a coupler head portion extending from a shank portion. The coupler head portion is configured to couple to a first coupler knuckle for coupling the railcar coupler to a second railcar coupler of an adjacent railcar. The coupler head portion comprises a nose portion and a gathering face extending from the nose portion for engaging a second coupler knuckle coupled to the second railcar coupler. The coupler head portion comprises a guard arm portion extending from the nose portion towards the shank portion. The guard arm portion comprises a minimum height less than a height of the shank portion where the guard arm portion meets the shank portion. | 12-30-2010 |
| 20110163059 | Railcar Coupler System and Method - A railcar coupler includes a coupler head portion extending from a shank portion. The coupler head portion is configured to couple to a first coupler knuckle for coupling the railcar coupler to a second railcar coupler of an adjacent railcar. The coupler head portion comprises a nose portion and a gathering face extending from the nose portion for engaging a second coupler knuckle coupled to the second railcar coupler. The coupler head portion comprises a guard arm portion extending from the nose portion towards the shank portion. The coupler head portion comprises a horn portion having a back surface. A distance between the back surface of the horn portion and a nose end of the guard arm portion is less than 11 inches. The coupler head portion comprises a locklifter shelf less than 2 inches above a bottom edge of the coupler. | 07-07-2011 |